Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07489573 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv6
  2. Trial sites expanded: 7 → 10 locationsv5
  3. Trial sites expanded: 1 → 7 locationsv4
  4. Recruitment opened Study sites: 0 to 1 · Start date changed from estimate of Aug 21, 2026 to Jun 1, 2026v3 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Aug 21, 2026 to Jun 1, 2026
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).
Trial Details
NCT Number NCT07489573
Lead Sponsor Novartis Pharmaceuticals
Conditions Hidradenitis Suppurativa (HS)
Enrollment 36 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov